![glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)
glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1
Description
The needle is shorter, the injection depth is pre-set, and the dose is dialed rather than drawn
![glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1](https://www.e-enm.org/upload/thumbnails/enm-31-258-g001.jpg)
Also worth noting these are relative risk reductions
![glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffd4/12904707/4fa38c7b0690/jci-136-194748-g202.jpg)
Proton pump inhibitors reduce gallbladder function
![glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12933-024-02500-y/MediaObjects/12933_2024_2500_Figa_HTML.png)
Alipanahi, B., Delong, A., Weirauch, M
![glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1](https://assets.radcliffecardiology.com/s3fs-public/article/2025-05/Figure3-Guideline-Recommendations.png?VersionId=HEwsyPwt7bPNVa1O9xXI4pMhddv6cw..)
Disagreements were resolved through consensus or a third reviewer (AFW)
![glp-1 cardiovascular benefit disease continuum-GLP-1 action. Adapted from [46] Cardiovascular Effects of Glucagon-Like Peptide-1](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3830179643421147377)
